Introduction
T helper (Th) cells and cytokines play major roles in the development and maintenance of the inflammatory process in multiple sclerosis (MS). Th cells are divided into functional subsets defined according to their cytokine profile and pathogenic relevance. Originally, MS was regarded as a Th1-mediated disease, underscored by the observation that treatment with Interferon-γ, the Th1signature cytokine, in fact worsened the clinical course of MS (1) . In contrast, Th2 immunity, including IL-4 and IL-13, was ascribed a protective role in MS by counteracting Th1 immunity, although this paradigm has been somewhat questioned (2) .
More recently, Th17 immunity, named after the signature cytokine IL-17, has been linked to MS pathogenesis (3) while regulatory T (Treg) cells were considered protective (4) . Treg cells dampen inflammation and counteract autoimmunity in several ways, one being through secretion of IL-10, a cytokine in general showing anti-inflammatory actions (5) . A dysfunction of Treg cells and imbalance of suppressive Th subsets has been suggested in MS (6, 7) .
Despite the launching of new drugs, Interferon-beta (IFN-β) and Glatiramer acetate are still used as first line treatments in many patients with relapsing remitting (RR) MS. IFN-β is usually well tolerated, reduces the relapse frequency by approximately 30% and has longterm beneficial effects on disability (8) . However it is well known that side-effects are sometimes prominent and that a substantial portion of patients (10-50%) do not respond to treatment, which is not only due to the induction of antibodies against the drug (9) . Thus, a possibility to predict the treatment response is therefore much wanted and it would therefore be important to better understand the mechanisms of action for IFN-β in relation to disease development. Although several mechanisms of IFN-β were indicated, including anti-IFN-β effect on cytokines in MS 4 Kvarnström et al.
inflammatory effects, diminished trafficking of T cells into the central nervous system (CNS)
and effects on antigen-presenting cells, the precise effects are not fully understood (8) .
Interestingly, the involvement of Th17 mediated immunity has come in focus not only for MS development but also because it's potential role in IFN-β therapy. Thus, IFN-β was shown to reduce IL-17 production directly or indirectly by reduction of osteopontin and induction of IL-27 (10) . Consequently, studies have demonstrated that IFN-β may exert its effect in MS by reduction of IL-17-associated immunity (11) (12) (13) (14) . In contrast, it has been
proposed that IFN-β may worsen disease outcome in a subgroup of MS patients (15) , based on findings that IFN-β worsened Th17-induced EAE, while it was beneficial in Th1-induced EAE. These data were in accordance with higher serum levels of IL-17F in a group of nonresponder MS patients (16) . It has also been shown that IL-17A levels in blood were numerically higher at baseline and throughout the course of IFN-β treatment in a subset of RRMS patients with relapses compared to those without relapses (17) . A recent study, however, showed that IL-17F does not predict poor response to IFN-β in RRMS (18) .
Although consistent data indicate that IFN-β acts by reduction of Th17-mediated immunity, divergent results concerning IL-17 as a predictor of response to IFN-β thus exist. In this prospective study we report longitudinal changes in Th1, Th2 and Th17 associated cytokines during the first year of IFN-β therapy. We also evaluated if pre-or post-treatment IL-17A levels were associated with response to treatment.
IFN-β effect on cytokines in MS None of the patients had any relapse within the last month prior to inclusion, and none received immunomodulating therapy within 6 months before onset. The patients received treatment with either IFN-β 1a (n = 12) (Avonex, BiogenIdec; Rebif, Merck Serono) or IFN-β 1b (n =13) (Betaferon, Schering). Patients without clinical relapse during one year of treatment were judged to be responders (n = 17), whereas patients with one or more relapses (n = 2), or increased disability according to Kurtzke Expanded Disability Status Scale (EDSS) of at least 0.5 step (n = 6), were judged as non-responders. Three patients interrupted the treatment during the study period because of adverse effects. Peripheral blood was collected before onset of treatment and 6 weeks, 3 months, 6 months, and 12 months after.
Some patients were lost to follow-up because they had moved from the catchment area or denied further extra blood sampling. Also some blood samples were lost due to technical laboratory difficulties or shortage of sample volume or cell numbers. Therefore the number of observations ranged between 14 and 24 pre-treatment and between 9 and 17 after one year.
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The samples were drawn at least 9 hours after the last injection. The study was approved by the Regional Ethics Committee for Human Research at the University Hospital of Linköping.
Antigens and mitogens
The myelin antigens used were two peptides from myelin oligodendrocyte glycoprotein 
Cell preparation
PBMCs were separated from heparinised venous blood by gradient centrifugation on Lymphoprep (Nycomed Pharma AS, Oslo, Norway), according to Bøyum (23 (24) . The cells were counted under a phase contrast microscopy.
Since mainly lymphokines were studied, the cell density was adjusted to a fixed number of lymphocytes (1 x 10 6 /ml), implying that a number of monocytes were present in addition to the lymphocytes.
ELISPOT
ELISPOT for detection of IFN-, IL-4-and IL-10-secreting cells was performed as previously described (25) . All antibodies were purchased from Mabtech (Stockholm, Sweden). PBMCs were incubated with or without antigens for 48 hours. Mean values of triplicates were calculated for the spontaneous secretion and for antigen-induced secretion.
Spots were counted under a dissection microscope. To obtain the number of antigen-specific cells, the values of the non-stimulated cells were subtracted from the values of the stimulated cells. Some wells on each plate were incubated with TCM only (without cells) but otherwise treated likewise. No or occasionally a few spots were seen in these wells.
ELISA
PBMCs were incubated with or without antigens for 48 hours before supernatants were collected and stored at -70°C until analysis. The ELISA was performed as described previously (26) . Microtitre plates (Costar, Cambridge, MA, U.S.) were coated (50 L/well) with 4 g/mL of anti-human IL-13 or IL-17A antibody, respectively (R&D Systems, Abingdon, UK) in carbonate buffer (pH 9.6), over night in room temperature. The plates were washed 4 times with PBS-Tween, followed by incubation on a plate shaker for 1 h at room temperature with 100 L/well of 2 % low-fat milk in PBS, to block non-specific protein IFN-β effect on cytokines in MS figure 3B ). In serum, a similar pattern in IL-17A concentrations was suggested, both considering the whole group ( figure 2D ) and according to clinical response (figure 3C), although no statistically significant changes were found. For cytokines other than IL-17A, there were no differences when comparing responders and nonresponders at baseline or follow-up.
One potential confounder of IL-17A responses related to clinical response would be if responders and non-responders differed in any respect. RR MS seemed to be more common in responders (table 1) , although the frequency did not statistically differ from that in nonresponders (p=0.10). Even more important, IL-17A levels were similar in responders versus non-responders (no significant difference was found, p= 0.3 -0.6 at different time points). Kvarnström et al.
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All other parameters (table 1) were similar across the groups. No significant differences in IL-17A secretion occurred between IFN-β 1a and IFN-β 1b treated patients.
Discussion
The main aim of the present study was to prospectively assess longitudinal changes in Th1, Th2 and Th17-associated cytokine secretion in patients treated with IFN-β. In general, few changes occurred during the course. After one year of treatment, the only significant changes were a reduction in IL-17A secretion and an increase in the number of IL-10 secreting cells.
Interestingly, these finding mirror changes as predicted by detailed in vitro mechanistic studies of IL-17 (9) (10) (11) (12) 14) and . Another main finding of our study was the potential difference between responders and non-responders in IL-17A levels before and after treatment.
Th17-mediated immunity has come into focus in MS because of its involvement in EAE as
well as in MS pathology (16) . Interestingly, a reduction in IL-17 production was recently reported as an important mechanism of action for IFN-β (10). Also, Th17 cells showed a higher expression of type-1-interferon receptors as compared with Th1 cells, suggesting Th17 cells to be selectively targeted by IFN-β (12). The detailed mechanisms involved in IFN-β actions were recently reported including the ability of IFN-β to inhibit human Th17 cell differentiation (13) , to inhibit IL-17-as well as osteopontin production in human CD4+ cells (11) , and to inhibit IL-17 production by dendritic cells in MS patients, the latter mechanism probably mediated through IL-27 induction (14) . We here report the longitudinal effects on IL-17A during INF-β treatment. We show that ex vivo induced IL-17A secretion was 12 decreased after one year of treatment. In addition to the effect on IL-17A, we also noted an increase in the number of IL-10 secreting cells, which is in line with previous reports (28-31).
IL-10 is an immunomodulatory cytokine with predominantly suppressive actions that is produced by many cell types including regulatory T cells (5) as well as regulatory B cells (32) . Interestingly, mechanistic studies recently showed that IFN-β induced IL-10 in CD4 cells (13, 16) . Collectively, data indicate that reduction of IL-17 and induction of IL-10 seems to be important effects induced by IFN-β.
Regarding Th1 and Th2 associated cytokines we did not see any differences after 12 months compared with pre-treatment levels. During the course, myelin antigen-induced IL-4 secretion was reduced after three months, which corroborates some previous findings of decreased IL-4 during IFN-β treatment (33, 34) , while other studies showed no difference (25, 35) , or increased IL-4 (28, 36) . The inconsistencies in previous data surely depend on differences in methodology as well as in time points of sampling. For the Th1-associated cytokine IFN-γ we did not find any changes during the course of treatment, which corroborates some previous studies (35, 37) , while others showed a decrease (25, 28, 33, 36) or an increase (38) . Thus, previous data are inconsistent also regarding Th1 cytokines. Taken together, there is no consensus regarding IFN-β effects on Th1/Th2 associated cytokines. In that sense, our findings of no sustained changes in Th1/Th2 cytokines after one year of treatment would be expected. We therefore propose that IFN-β may preferentially induce long-term changes in the IL-17/IL-10 axis rather than in the IFN-γ/IL-4/IL-13 axis.
Since there is a substantial portion of patients that do not respond to IFN-β treatment (in addition to those caused by antibodies against IFN-β), a possibility to predict treatment IFN-β effect on cytokines in MS 13 Kvarnström et al.
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outcome would be o great value. It was recently proposed that IFN-β therapy was beneficial in EAE associated with Th1 pathology, while in Th17 pathology IFN-β treatment could even worsen disease outcome (16) . Consequently, it was noted that higher pre-treatment IL-17F levels were found in a subgroup of non-responder MS patients, which is in line with a lack of effect in individuals with Th17 associated pathology. In addition, IL-17A levels were reported to be numerically higher in relapsing versus non-relapsing RRMS patients at baseline and during one year follow-up of IFN-β treatment, reaching statistical significance at 6 months (17). However, in another and larger cohort of RRMS patients, IL-17F levels at baseline did not differ between good-and poor responders (18) . Regarding IL-17A levels before treatment, we found that IL-17A levels tended to be higher in our cohort of nonresponders compared with responders. We also measured IL-17A levels after one year of treatment and found that the responders showed a significant reduction after one year, while In conclusion, we show that IL-17A secretion of blood cells is decreased after one year of IFN-β treatment, which reflects recent in vitro studies of IFN-β effector mechanisms. Further, the decrease in IL-17A levels seemed to occur in both responders and non-responders, although the decrease was more pronounced in the responder group, suggesting that also individuals with Th17-mediated disease can respond to this treatment. The number of cells secreting the immunosuppressive IL-10 cytokine was increased after one year of treatment. In contrast, changes in Th1/Th2-associated cytokines were recorded early, but no sustained effects were observed after one year. Thus, the effects of IFN-β treatment seem to be more Progressive; y = years.
*Non-responders were defined as at least one relapse or an increase of at least 0.5 step in EDSS during one year of treatment.
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Figure legends 
